China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd, a biopharma focused on metabolic diseases, has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its efsubaglutide alfa to treat type 2 diabetes (T2D). This approval marks a significant milestone in the development and commercialization of efsubaglutide alfa, positioning Innogen to address significant unmet medical needs in diabetes management.
Drug Profile and Clinical Data
Efsubaglutide alfa is a next-generation ultra-long-acting glucagon-like peptide 1 (GLP-1) receptor agonist with an average half-life in T2D patients of up to 204 hours. Clinical studies have shown that efsubaglutide alfa exhibits a rapid onset of action and significant hypoglycemic effects. A 3mg dose of efsubaglutide alfa alone for 4 weeks reduced the patient’s glycated hemoglobin (HbA1c) level by 1.1%. After 24 weeks of treatment, HbA1c significantly decreased by 2.2% compared to baseline. For patients with baseline HbA1c < 8.5%, the HbA1c compliance rate was as high as 81.5% after 24 weeks of efsubaglutide alfa as a monotherapy. For new-onset T2D patients, the remission rate of diabetes reached 60% 3 months after drug withdrawal.
Additional Benefits and Ease of Use
While lowering blood sugar, efsubaglutide alfa is also expected to improve metabolism, with potential weight loss and cardiovascular benefits. The drug does not require titration, making it easy to use and convenient for patients. These features position efsubaglutide alfa as a promising candidate for improving patient outcomes in the management of type 2 diabetes.-Fineline Info & Tech
Leave a Reply